Active	Status	Sponsor type	Region	Phase	Filter
6 Active 16 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ztalmy (ganaxolone oral) / Marinus
2021-003441-38: A trial for children and adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy to determine how effective Ganaxolone treatment is.	Ongoing	3	200	Europe	Ganaxolone, Oral suspension	Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc., Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.	Tuberous Sclerosis Complex (TSC)-related epilepsy, Seizures due to Tuberous Sclerosis Complex (TSC), Diseases [C] - Nervous System Diseases [C10]
TrustTSC, NCT05323734 / 2021-003441-38: Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy	Completed	3	128	Europe, Canada, US, RoW	Ganaxalone, Placebo	Marinus Pharmaceuticals, Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.	Tuberous Sclerosis Complex	09/24	10/24
NCT05249556: Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old	Not yet recruiting	3	20	NA	Ganaxolone, Active Drug, Placebo, Inactive	Marinus Pharmaceuticals	CDKL5 Deficiency Disorder	12/26	03/27
NCT05604170: Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy	Enrolling by invitation	3	132	Europe, Canada, US, RoW	Ganaxolone	Marinus Pharmaceuticals	Tuberous Sclerosis Complex	06/27	06/27
NCT02766920: Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone	Not yet recruiting	N/A	10	US	CCD-1042	Massachusetts General Hospital	Major Depressive Disorder	08/18
CDD, NCT04678479: Ganaxolone Expanded Access Program Compassionate Use	No Longer Available	N/A		NA	Ganaxolone	Marinus Pharmaceuticals	CDKL5 Disorder